vs

Side-by-side financial comparison of Datacentrex, Inc. (DTCX) and Vivos Therapeutics, Inc. (VVOS). Click either name above to swap in a different company.

Datacentrex, Inc. is the larger business by last-quarter revenue ($7.0M vs $3.8M, roughly 1.8× Vivos Therapeutics, Inc.). Datacentrex, Inc. runs the higher net margin — 75.8% vs -180.3%, a 256.1% gap on every dollar of revenue. On growth, Datacentrex, Inc. posted the faster year-over-year revenue change (4463314.1% vs 3.4%).

Datacentrex, Inc. is a technology infrastructure service provider offering colocation, managed cloud hosting, and enterprise IT support solutions. It serves small, medium and enterprise clients as well as public sector organizations across North America, focusing on reliable, secure data center operations and customized digital infrastructure services.

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.

DTCX vs VVOS — Head-to-Head

Bigger by revenue
DTCX
DTCX
1.8× larger
DTCX
$7.0M
$3.8M
VVOS
Growing faster (revenue YoY)
DTCX
DTCX
+4463310.7% gap
DTCX
4463314.1%
3.4%
VVOS
Higher net margin
DTCX
DTCX
256.1% more per $
DTCX
75.8%
-180.3%
VVOS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DTCX
DTCX
VVOS
VVOS
Revenue
$7.0M
$3.8M
Net Profit
$5.3M
$-6.9M
Gross Margin
78.1%
Operating Margin
87.2%
-166.8%
Net Margin
75.8%
-180.3%
Revenue YoY
4463314.1%
3.4%
Net Profit YoY
295.3%
-143.8%
EPS (diluted)
$0.65
$-0.58

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DTCX
DTCX
VVOS
VVOS
Q4 25
$7.0M
$3.8M
Q3 25
$6.8M
Q2 25
$3.8M
Q1 25
$3.0M
Q4 24
$3.7M
Q3 24
$3.9M
Q2 24
$4.1M
Q1 24
$3.4M
Net Profit
DTCX
DTCX
VVOS
VVOS
Q4 25
$5.3M
$-6.9M
Q3 25
$-5.4M
Q2 25
$-5.0M
Q1 25
$-3.9M
Q4 24
$-2.8M
Q3 24
$-2.6M
Q2 24
$-1.9M
Q1 24
$-3.8M
Gross Margin
DTCX
DTCX
VVOS
VVOS
Q4 25
78.1%
Q3 25
58.0%
Q2 25
55.2%
Q1 25
50.0%
Q4 24
56.7%
Q3 24
60.5%
Q2 24
65.4%
Q1 24
56.7%
Operating Margin
DTCX
DTCX
VVOS
VVOS
Q4 25
87.2%
-166.8%
Q3 25
-69.8%
Q2 25
-127.4%
Q1 25
-129.9%
Q4 24
-75.9%
Q3 24
-68.5%
Q2 24
-47.8%
Q1 24
-110.7%
Net Margin
DTCX
DTCX
VVOS
VVOS
Q4 25
75.8%
-180.3%
Q3 25
-79.6%
Q2 25
-131.2%
Q1 25
-128.1%
Q4 24
-76.4%
Q3 24
-67.8%
Q2 24
-47.6%
Q1 24
-110.1%
EPS (diluted)
DTCX
DTCX
VVOS
VVOS
Q4 25
$0.65
$-0.58
Q3 25
$-0.49
Q2 25
$-0.55
Q1 25
$-0.45
Q4 24
$0.41
Q3 24
$-0.40
Q2 24
$-0.60
Q1 24
$-1.63

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DTCX
DTCX
VVOS
VVOS
Cash + ST InvestmentsLiquidity on hand
$38.9M
$2.0M
Total DebtLower is stronger
$2.9M
Stockholders' EquityBook value
$66.2M
$-1.5M
Total Assets
$66.8M
$25.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DTCX
DTCX
VVOS
VVOS
Q4 25
$38.9M
$2.0M
Q3 25
$3.1M
Q2 25
$4.4M
Q1 25
$2.3M
Q4 24
$6.3M
Q3 24
$6.3M
Q2 24
$6.9M
Q1 24
$2.6M
Total Debt
DTCX
DTCX
VVOS
VVOS
Q4 25
$2.9M
Q3 25
Q2 25
Q1 25
Q4 24
$1.2M
Q3 24
$1.2M
Q2 24
$1.2M
Q1 24
Stockholders' Equity
DTCX
DTCX
VVOS
VVOS
Q4 25
$66.2M
$-1.5M
Q3 25
$2.5M
Q2 25
$4.6M
Q1 25
$4.4M
Q4 24
$8.0M
Q3 24
$7.7M
Q2 24
$6.3M
Q1 24
$582.0K
Total Assets
DTCX
DTCX
VVOS
VVOS
Q4 25
$66.8M
$25.2M
Q3 25
$25.6M
Q2 25
$26.0M
Q1 25
$11.3M
Q4 24
$15.3M
Q3 24
$15.3M
Q2 24
$15.8M
Q1 24
$11.8M
Debt / Equity
DTCX
DTCX
VVOS
VVOS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.15×
Q3 24
0.16×
Q2 24
0.19×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DTCX
DTCX
VVOS
VVOS
Operating Cash FlowLast quarter
$-1.5M
$-3.8M
Free Cash FlowOCF − Capex
$-5.3M
FCF MarginFCF / Revenue
-139.7%
Capex IntensityCapex / Revenue
40.0%
Cash ConversionOCF / Net Profit
-0.28×
TTM Free Cash FlowTrailing 4 quarters
$-17.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DTCX
DTCX
VVOS
VVOS
Q4 25
$-1.5M
$-3.8M
Q3 25
$-4.2M
Q2 25
$-3.5M
Q1 25
$-3.8M
Q4 24
$-2.9M
Q3 24
$-4.2M
Q2 24
$-3.0M
Q1 24
$-2.5M
Free Cash Flow
DTCX
DTCX
VVOS
VVOS
Q4 25
$-5.3M
Q3 25
$-4.2M
Q2 25
$-4.3M
Q1 25
$-3.9M
Q4 24
$-3.1M
Q3 24
$-4.4M
Q2 24
$-3.1M
Q1 24
$-2.7M
FCF Margin
DTCX
DTCX
VVOS
VVOS
Q4 25
-139.7%
Q3 25
-62.6%
Q2 25
-111.6%
Q1 25
-129.9%
Q4 24
-84.0%
Q3 24
-113.4%
Q2 24
-76.7%
Q1 24
-78.0%
Capex Intensity
DTCX
DTCX
VVOS
VVOS
Q4 25
40.0%
Q3 25
1.2%
Q2 25
20.2%
Q1 25
4.0%
Q4 24
4.5%
Q3 24
5.0%
Q2 24
1.5%
Q1 24
4.4%
Cash Conversion
DTCX
DTCX
VVOS
VVOS
Q4 25
-0.28×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DTCX
DTCX

Segment breakdown not available.

VVOS
VVOS

Services$3.2M84%
Products$594.0K16%

Related Comparisons